In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.
The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space.
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock’s growth potential.
/Incyte%20Corp_%20logo%20and%20bar%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Wall Street is keeping a confident yet pragmatic stance on Incyte Corporation, supported by steady growth and a promising pipeline.
Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.
What makes analysts so bullish about these three names from the sector?
/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance.
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.
/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.